trending Market Intelligence /marketintelligence/en/news-insights/trending/h6kjgtpigi4xqdh2e6ehng2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

ADMA Biologics' Fla. manufacturing facility gets US FDA clearance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ADMA Biologics' Fla. manufacturing facility gets US FDA clearance

ADMA Biologics Inc. said the U.S. Food and Drug Administration cleared its manufacturing facility in Boca Raton, Fla.

The regulator updated the facility's compliance status to voluntary action indicated, which means that objectionable conditions were found and documented but that the FDA will not make or recommend regulatory action.

Following the improved compliance status, ADMA intends to resubmit its biologics license application for its lead drug, RI-002, in the third quarter of 2018.

RI-002 is an investigational treatment of primary humoral immunodeficiency disease, a group of diseases caused by impaired humoral immunity, or antibody-mediated immune responses.